Mainz Biomed announced the addition of Bioclinica to its esteemed network of laboratory partners. Bioclinica will play a crucial role in supporting the commercialization efforts of ColoAlert, Mainz Biomed’s flagship product-a highly effective and user-friendly at-home detection test for colorectal cancer, or CRC. This strategic collaboration marks another milestone in Mainz Biomed’s mission to revolutionize the diagnosis and prevention of life-threatening diseases, particularly CRC, which continues to be the second most lethal cancer in Europe.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MYNZ:
- Mainz Biomed Expands into Romania Through Partnership with Bioclinica
- Mainz Biomed Expands Commercial Footprint into Poland
- Mainz Biomed Processes First Patients from Colorectal Cancer Screening Campaign Through its Corporate Health Portal in Partnership with Zöeller-Kipper
- Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate Update
- Mainz Biomed B.V. (MYNZ) Q1 Earnings Cheat Sheet